Randomized Clinical Trial
Copyright ©The Author(s) 2022.
World J Gastroenterol. Dec 7, 2022; 28(45): 6397-6409
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6397
Table 2 Procedure-related outcomes in this study
Parameter
EMR-P group, %
CEMR group, %
P value
ITT analysisn = 110n = 110
      En bloc resection103 (93.6) [87.5-96.9]95 (86.4) [78.7-91.6]0.072
      R0 resection89 (80.9) [72.6-87.2]86 (78.2) [69.6-84.9]0.616
      R1 resection9 (8.2) [4.4-14.8]9 (8.2) [4.4-14.8]> 0.999
      RX resection6 (5.5) [2.5-11.4]6 (5.5) [2.5-11.4]> 0.999
PP analysisn = 106n = 107
      En bloc resection100 (94.3) [88.2-97.4]92 (86.0) [78.2-91.3]0.041
      R0 resection86 (81.1) [72.6-87.4]83 (77.6) [68.8-84.4]0.521
      R1 resection9 (8.4) [4.5-15.4]9 (8.5) [4.5-15.2]0.983
      RX resection6 (5.7) [2.6-11.8]6 (5.6) [2.6-11.7]0.987
Histological type, n (%)n = 110n = 1100.354
Adenoma82 (74.5)85 (77.3)
Tubular adenoma with low-grade dysplasia62 (56.4)63 (57.3)
Tubular adenoma with high-grade dysplasia6 (5.5)7 (6.4)
Villous adenoma with low-grade dysplasia2 (1.8)1 (0.9)
Villous adenoma with high-grade dysplasia0 (0.0)0 (0.0)
Tubular villous adenoma with low-grade dysplasia10 (9.1)12 (10.9)
Tubular villous adenoma with high-grade dysplasia2 (1.8)2 (1.8)
Hyperplastic11 (10.0)14 (12.7)
Serrated lesions9 (8.2)7 (6.4)
Cancer4 (3.6)4 (3.6)
Intramucosal adenocarcinoma3 (2.7)4 (3.6)
Submucosal invasive adenocarcinoma1 (0.9)0 (0.0)
Other4 (3.6)0 (0.0)
Procedure time (min)6.4 (4.5, 10.3)3.0 (1.9, 6.2)< 0.001